Keytruda (pembrolizumab)

Keytruda is FDA-approved to treat a wide range of cancers, including:

Keytruda may be used off-label in certain rare tumor types or as part of clinical trials when conventional therapies have failed. However, such uses require close supervision by an oncologist and institutional approval.

Keytruda is a monoclonal antibody classified as an anti-PD-1 checkpoint inhibitor. It works by blocking the PD-1 pathway, helping the immune system recognize and attack cancer cells. It is part of a new class of immunotherapies known as immune checkpoint inhibitors that have changed the standard of care for many cancer types.

USA: Merck & Co., Inc.
Mexico: Merck Sharp & Dohme de México, S.A. de C.V.
Canada: Merck Canada Inc.

Canada: ~30–40% savings compared to U.S. retail price
Mexico: ~25–35% savings compared to U.S. retail price

(Savings may vary depending on availability, controlled access, prescription requirements, and cold chain shipping.)

Availability may vary depending on insurance plans, pharmacy networks, and oncology center access.

This medication is accessed through fully licensed Canadian pharmacies regulated by Health Canada. All pharmacies included in the MedicalMex network undergo a rigorous review and verification process to ensure compliance with national standards, patient safety, and medication authenticity.

This medication is also available through certified pharmacies in Mexico regulated by COFEPRIS (Mexico’s national health authority). All partners in the MedicalMex network must pass a rigorous review and certification process before being approved for patient access.

All patients should be monitored by an oncologist familiar with immune checkpoint inhibitor management.

Opdivo (nivolumab)
Tecentriq (atezolizumab)
Imfinzi (durvalumab)
Yervoy (ipilimumab)
Targeted therapies (e.g., EGFR, ALK, BRAF inhibitors)
Chemotherapy
Radiation therapy
Clinical trials with novel immunotherapies